Abstract
Therapeutic options for metastatic melanoma have expanded dramatically over the past decade. Advances in tumor biology, immunotherapy, and adoptive cellular therapy are offering patients more options and requiring oncology advanced practitioners to develop familiarity with increasingly complex treatment modalities and care pathways. Speakers at JADPRO Live 2025 focused on extracutaneous melanoma—particularly mucosal and uveal melanoma—and highlighted novel immune-based therapies, including immune-mobilizing monoclonal T-cell receptors against cancer (ImmTACs) and tumor-infiltrating lymphocyte (TIL) therapy.
References
Chesney, J., Lewis, K. D., Kluger, H., Hamid, O., Whitman, E., Thomas, S., Wermke, M., Cusnir, M., Domingo-Musibay, E., Phan, G. Q., Kirkwood, J. M., , J. C., Orloff, M., Larkin, J., Weber, J., Furness, A. J. S., Khushalani, N. I., Medina, T., Egger, M. E., Graf Finckenstein, F.,…Sarnaik, A. (2022). Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. Journal for Immunotherapy of Cancer, 10(12), e005755. https://doi.org/10.1136/jitc-2022-005755
Hassel, J. C., Piperno-Neumann, S., Rutkowski, P., Baurain, J. F., Schlaak, M., Butler, M. O., Sullivan, R. J., Dummer, R., Kirkwood, J. M., Orloff, M., Sacco, J. J., Ochsenreither, S., Joshua, A. M., Gastaud, L., Curti, B., Piulats, J. M., Salama, A. K. S., Shoushtari, A. N., Demidov, L., Milhem, M., … Nathan, P. (2023). Three-year overall survival with tebentafusp in metastatic uveal melanoma. The New England Journal of Medicine, 389(24), 2256–2266. https://doi.org/10.1056/NEJMoa2304753
Rohaan, M. W., Borch, T. H., van den Berg, J. H., Met, Ö., Kessels, R., Geukes Foppen, M. H., Stoltenborg Granhøj, J., Nuijen, B., Nijenhuis, C., Jedema, I., van Zon, M., Scheij, S., Beijnen, J. H., Hansen, M., Voermans, C., Noringriis, I. M., Monberg, T. J., Holmstroem, R. B., Wever, L. D. V., van Dijk, M.,…Haanen, J. B. A. G. (2022). Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma. The New England Journal of Medicine, 387(23), 2113–2125. https://doi.org/10.1056/NEJMoa2210233
